亚太迷幻药市场 – 行业趋势及 2029 年预测

亚太地区迷幻药市场分析与洞察

迷幻药涉及多种化学物质，包括麦角酸二乙酰胺 (LSD) 和从植物中提取的化学物质。这些药物能够改变或增强感官知觉、思维过程、能量水平，据报道还能促进精神体验。

迷幻药可分为共情药和解离药（如苯基环己基哌啶 (PCP)）和血清素药（经典致幻剂），如 LSD。这两种迷幻药都会引起幻觉和感觉，此外，解离药会使人失去对自己身体或环境的控制，使他们感到与世隔绝。根据来源，迷幻药分为天然和合成两类。

这些药物广泛应用于治疗重度抑郁症、创伤后应激障碍、惊恐障碍、难治性抑郁症和阿片类药物成瘾等。迷幻药还有其他几个名字，例如麦角酸衍生物 (LSD) 也被称为吸墨纸、点、糖、酸、旅行和窗格，氯胺酮也被称为维生素 K、肿块、绿色、K/特殊 K、紫色和超酸，PCP 也被称为天使/天使尘、船/爱之船、和平、杀手杂草、超级草和臭氧。

亚太地区迷幻药市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场将以 11.3% 的复合年增长率增长，预计到 2029 年将从 2021 年的 2724 万美元增至 6370 万美元。

Market Definition

Psychedelic drugs involve various types of chemical substances including lysergic acid diethylamide (LSD) and chemical extracted from plants. These drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

The psychedelic drugs can be categorized into empathogens and dissociative drugs (such as phenylcyclohexyl piperidine (PCP)) and serotonergic (classic hallucinogens) such as LSD. Both types of psychedelic drugs can cause hallucinations and feeling of sensation, moreover, dissociative drugs can make a person to fell out of control from their body or environment and makes them feel disconnected. Based on the source, psychedelic drugs have been categorized under natural and synthetic types.

These drugs have wide applications in the treatment of major depressive disorder, post-traumatic stress disorder, panic disorder, treatment-resistant depression and opiate addiction among others. Psychedelic drugs are also known by several other names such as lysergic acid derivative (LSD) which are also known as blotter, dots, sugar, acid, trips and window pane, ketamine are also known as vitamin K, bump, green, K/special K, purple and super acid, PCP are also known as angel/angel dust, boat/love boat, peace, killer weed, super grass and ozone.

Psychedelic Drugs Market Dynamics

Drivers

• Ongoing Clinical Trials

The major depressive disorder has become a serious concern of health crisis in the modern world. The onset of clinical trials is to test the safety and efficacy of the designated drug, which is under a particular phase of a clinical trial. Depression is associated with greater deformities than most of other chronic illness and hence it poses as a risk factor for mortality. Most of the patients suffering from depression are not able to experience a complete tenacity of symptoms with antidepressant treatment. Certain clinical trials have been conducted to study the efficacy in the body. The ongoing clinical trials all over the regions would result in rapid drug approvals, enhanced drug portfolio, distribution of the psychedelics drugs in rehabilitation centres and increased awareness about the drug medication, which in turn is expected to act as driver for the growth of the market.

• Rise In Product Approvals

The approval of psychedelic drugs depends on numerous factors, but the vital factor is the approval from the principal medical authority. The U.S. Food and Drug Administration is the leading authority for the drug approvals in the U.S. The central body decides whether the medical drugs would ultimately reach the hands of the patients. Below provided are the clinical data by established medical studies that has been reviewed by FDA in order to evaluate the feasibility of developed drug compounds or products as treatments for specific mental ailments. The rise in product approvals would result in increased distribution of the medications across national and international countries, increased safety. It would deliver a positive growth in the market.

Opportunity

• Upcoming Rehabilitation Centers

The presence of upcoming rehabilitation centers, also termed as in patient rehabilitation hospitals would ensure the timely treatment of the patients suffering from PTSD, anxiety related disorders. These rehabilitation centers provide with the effective therapies and allow patients to achieve advanced drugs which improve the overall patient’s outcome. It would also devote to patients who would require anesthetic treatments for complicated surgeries, orthopedic, neurological, musculoskeletal, in order to stabilize the acute medical conditions.

Also, the increasing R&D activities in psychedelic drugs will provide structural integrity and future opportunities for the psychedelic drugs market in the forecast period of 2022-2029.

Restraint/Challenge

• Patent Expiry Of Psychedelic Drugs

However, the patent expiry of psychedelic drugs in some of the companies will impede the growth rate of psychedelic drugs market. Additionally, stringent rules and regulations will further challenge the market in the forecast period mentioned above.

This psychedelic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on psychedelic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post COVID-19 Impact on Psychedelic Drugs Market

The COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world’s population. Hence, the pandemic has effected positively on this market.

Recent Developments

• In August 2020, Janssen Pharmaceuticals, Inc. received approval for its Spravato nasal spray indicated for treatment of suicidal people. As approximately 11% to 12% of Americans suffers from major depressive disorder that led them to commit suicide, this approval provided these patients with a remarkable therapy and paved the way for the company to generate more revenue.
• In January 2020, Jazz Pharmaceuticals, Inc. has received the marketing authorization of solriamfetol (Sunosi) indicated for treatment of excessive daytime sleepiness in adults with narcolepsy. This authorization allowed the company to enhance product distribution network and to generate more revenue in the market

Asia-Pacific Psychedelic Drugs Market Scope

Asia-Pacific psychedelic drugs market is segmented into source, type, drugs, application, route of administration, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Source

• Synthetic
• Natural

On the basis of source, the Asia-Pacific psychedelic drugs market is segmented into synthetic and natural.

Type

• Empathogens
• Dissociatives
• Others

On the basis of type, the Asia-Pacific psychedelic drugs market is segmented into empathogens, dissociatives, and others.

Drugs

• Gamma-Hydroxybutyric Acid
• Ketamine
• Psilocybin
• Others

On the basis of drugs, the Asia-Pacific psychedelic drugs market is segmented into gamma-hydroxybutyric acid, ketamine, psilocybin and others.

Application

• Narcolepsy,
• Treatment Resistant Depression
• Major Depressive Disorder
• Opiate Addiction
• Post-Traumatic Stress Disorder
• Others

根据应用，亚太地区迷幻药市场分为发作性睡病、难治性抑郁症、重度抑郁症、阿片类药物成瘾、创伤后应激障碍等。

给药途径

• 口服
• 吸入
• 注射剂

根据给药途径，亚太地区迷幻药市场分为口服、吸入和注射。

最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

根据最终用户，亚太迷幻药市场分为医院、专科诊所、家庭护理和其他。

分销渠道

• 医院药房
• 零售药店
• 网上药店

根据分销渠道，亚太迷幻药市场分为医院药房、零售药房和网上药房。

迷幻药市场区域分析/见解

对迷幻药市场进行了分析，并按国家、来源、类型、药物、应用、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。

该迷幻药报告涉及的国家包括印度、澳大利亚、韩国、新加坡和马来西亚。

印度在迷幻药市场的市场份额和市场收入方面占据主导地位，并将在预测期内继续保持主导地位。这是因为该地区越来越多人接受迷幻药治疗抑郁症，而且快速的研究发展也推动了市场的发展。

报告的国家部分还提供了影响单个市场因素和市场法规变化的信息，这些因素和变化会影响市场的当前和未来趋势。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。

竞争格局和迷幻药 份额分析

迷幻药市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对迷幻药市场的关注有关。

迷幻药市场的一些主要参与者包括杨森全球服务有限公司（强生服务公司的子公司）、辉瑞公司、罗氏公司等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区和供应商份额分析。如有进一步询问，请要求分析师致电

SKU-67886